公开(公告)号：US20140213540A1

公开(公告)日：2014-07-31

申请号：US14220534

申请日：2014-03-20

申请人： IDENIX PHARMACEUTICALS, INC. ,  L'UNIVERSITE MONTPELLIER II ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITA DEGLI STUDI DI CAGLIARI

发明人： Richard STORER ,  Gilles GOSSELIN ,  Jean-Pierre SOMMADOSSI ,  Paolo LACOLLA

IPC分类号： C07H19/16 ,  C07H19/056 ,  C07H19/06

CPC分类号： C07H19/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/60 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/056 ,  C07H19/06 ,  C07H19/22 ,  A61K2300/00

摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

公开(公告)号：US20150017124A1

公开(公告)日：2015-01-15

申请号：US14334381

申请日：2014-07-17

申请人： IDENIX PHARMACEUTICALS, INC. ,  UNIVERSITA DEGLI STUDI DI CAGLIARI ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  L'UNIVERSITE MONTPELLIER II

发明人： Richard STORER ,  Gilles GOSSELIN ,  Jean-Pierre SOMMADOSSI ,  Paolo LACOLLA

IPC分类号： C07H19/16 ,  A61K38/21 ,  A61K31/7072 ,  A61K31/7076 ,  C07H19/06 ,  A61K31/7068 ,  A61K31/7056 ,  A61K47/48

CPC分类号： C07H19/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/60 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/056 ,  C07H19/06 ,  C07H19/22 ,  A61K2300/00

摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

摘要翻译： 描述了1'，2'，3'或4'-支化核苷的2'和/或3'前药及其药学上可接受的盐和衍生物。 这些前药可用于预防和治疗黄病毒科感染，包括HCV感染和其他相关病症。 描述本发明前药的化合物和组合物。 还提供了包括施用有效量的本发明前药或其药学上可接受的盐或衍生物的方法和用途。 这些药物可以任选地与另外的抗病毒剂组合或改变来施用，以预防或治疗黄病毒科感染和其他相关病症。

公开(公告)号：US20170088577A1

公开(公告)日：2017-03-30

申请号：US15379415

申请日：2016-12-14

申请人： Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari ,  Centre National De La Recherche Scientifique ,  Universite de Montpellier

发明人： Richard STORER ,  Gilles GOSSELIN ,  Jean-Pierre SOMMADOSSI ,  Paolo LACOLLA

IPC分类号： C07H19/16 ,  A61K38/21 ,  A61K9/20 ,  A61K9/48 ,  C07H19/056 ,  A61K31/7068 ,  A61K31/7076 ,  A61K31/7072 ,  A61K31/7056 ,  A61K31/708 ,  A61K45/06 ,  C07H19/06

CPC分类号： C07H19/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/60 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/056 ,  C07H19/06 ,  C07H19/22 ,  A61K2300/00

摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

公开(公告)号：US20140234251A1

公开(公告)日：2014-08-21

申请号：US14269003

申请日：2014-05-02

申请人： Indenix Pharmaceuticals, Inc. ,  The Centre National de la Recherche Scientifique ,  L'Universite Montpellier II

发明人： Richard STORER ,  Gilles GOSSELIN ,  David DUKHAN ,  Frederic LEROY

IPC分类号： A61K31/706 ,  A61K45/06 ,  C07H19/04

CPC分类号： A61K31/706 ,  A61K31/00 ,  A61K45/06 ,  C07H19/04 ,  C07H19/044 ,  C07H19/052 ,  C07H19/056 ,  C07H19/23

摘要： This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.

摘要翻译： 本发明涉及用于治疗感染丙型肝炎，黄病毒和/或瘟病毒的宿主，特别是人的方法，包括向该宿主施用有效量的抗HCV生物活性戊呋喃核苷，其中戊呋喃核苷碱基是任选的 取代的2-氮杂嘌呤。 任选取代的五氟鸟苷或其盐或前药可以单独施用或与一种或多种任选取代的五氟鸟苷或其它抗病毒剂组合施用。